Quartier, Pierre <br/><br/>
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).  [electronic resource] 

 -  Annals of the rheumatic diseases  May 2011 
 - 747-54 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1468-2060 
<br/><br/><label>Standard No.: </label>10.1136/ard.2010.134254  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Antibodies, Bacterial--biosynthesis<br/>Antirheumatic Agents--adverse effects<br/>Arthritis, Juvenile--blood<br/>Biomarkers--blood<br/>Blood Sedimentation<br/>C-Reactive Protein--metabolism<br/>Child<br/>Child, Preschool<br/>Double-Blind Method<br/>Female<br/>Gene Expression Profiling--methods<br/>Humans<br/>Interleukin 1 Receptor Antagonist Protein--adverse effects<br/>Male<br/>Pneumococcal Vaccines--immunology<br/>Polysaccharides, Bacterial--immunology<br/>Severity of Illness Index<br/>Treatment Outcome<br/>Young Adult